Navigation Links
Simultaneous Applications Submitted to FDA and EMA for Siltuximab for the Treatment of Multicentric Castleman Disease, a Rare Blood Disorder
Date:9/3/2013

RARITAN, N.J., Sept. 3, 2013 /PRNewswire/ -- Janssen Research & Development, LLC ("Janssen") announced the simultaneous submissions of a Biologic License Application (BLA) to the United States Food and Drug Administration (U.S. FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for siltuximab for the treatment of patients with multicentric Castleman disease (MCD) who are HIV-negative and human herpes virus-8 (HHV-8)-negative.

MCD is a rare disorder in which lymphocytes, a certain type of white blood cells, are over-produced and lead to enlargement of lymph nodes.1, 2 This can cause a variety of symptoms and weaken the immune system, making it hard to fight infection. Infections in people with MCD can be very serious and may even be fatal.3 Currently, there are no approved treatments in the U.S. or European Union (EU) for this rare blood disorder.

"We're proud of our work on siltuximab. As a rare disease with a small patient population, MCD is an area of significant unmet need," said Peter F. Lebowitz, M.D., Ph.D., global oncology therapeutic area head, Janssen. "Siltuximab works by targeting interleukin-6 which appears to be the critical driver of this disease. By focusing on core biologic mechanisms, we now have the potential of helping patients with a condition that is challenging to treat."  

Siltuximab has been granted orphan drug status in MCD in the U.S. and EU. The siltuximab regulatory submissions include data from a randomized, multi-national, double-blind, placebo-controlled study (MCD2001) and data from two non-randomized supportive studies. The MCD2001 study assessed the efficacy and safety of siltuximab plus best supportive care (BSC) compared with placebo plus BSC in patients with MCD.4 In the study, 79 patients were randomly assigned in a 2:1 ratio to one of the two treatment
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. First Large-Scale Population-Based Study in the U.S. Shows Hologics 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection
2. Philips IMR offers new capabilities to simultaneously reduce CT Radiation and enhance image quality
3. Ventana Receives FDA Clearance for p53 (DO-7) Image Analysis and Digital Read Applications
4. Rubicon Genomics Launches ThruPLEX™ Family of Sample Preparation Products for Next Generation Sequencing Applications
5. Philips demonstrates innovations in nuclear medicine imaging with a comprehensive portfolio of NM applications for IntelliSpace Portal
6. Clinical Safety Data for ChromaDex®s Patented pTeroPure® (pterostilbene) Released at 6th World Congress on Polyphenols Applications in Paris
7. UltraTape announces Cleanroom Labels for Cryogenic Laboratory applications
8. New, Affordable Flow Cytometer Cell Sorter Expands Access to Wider Range of Life Science Applications
9. New Wireless Keyboard Rechargeable, Washable for Healthcare Applications
10. Frost & Sullivan: Label-Free Technology is a High Potential Market with Myriad Unexplored Applications
11. Radiotherapy Devices Market By Technology, Applications & Products (2011 - 2016)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Cadence Fitness & Health Center has been ... Fitness Association, a non-profit organization assisting medically integrated health ... Cadence Fitness & Health Center is the only certified ... the Chicagoland area. "The certification means the ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... – Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Analysis Insulin Pumps ...
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Va., Nov. 9, 2010 MicroAire Surgical Instruments LLC ... an agreement to settle a suit accusing Arthrex of ... the patented technology that MicroAire owns for minimally invasive ... K. Moon of the U.S. District Court for the ...
... MYSTIC, Conn., Nov. 9, 2010 Amarin Corporation plc (Nasdaq: ... Wednesday, November 10, 2010 at 11:00 am Eastern Time (4:00 ... the third quarter, including a progress update of the Company,s ... trials of its lead product candidate AMR101 for treating elevated ...
Cached Medicine Technology:MicroAire and Arthrex Agree to Amicable Settlement on ECTR Patent 2Amarin Corporation to Host Investor Conference Call on Wednesday, November 10, 2010 2
(Date:4/22/2014)... primary care for low-income patients may ease the ... while improving patient health, researchers have concluded. , ... clinics that avoid costs associated with insurance administration ... admission rates and emergency room visits, according to ... , The researchers estimated that the major ...
(Date:4/22/2014)... for Molecular Pathology (AMP) released a report today ... on recommendations for a molecular diagnostics curriculum at ... The report was prepared by the Medical Laboratory ... Training and Education Committee. "Our goal was to ... laboratory scientists appropriately in order to manage the ...
(Date:4/22/2014)... in German . ... molecules, but their mode of action is complex: In ... and behavior, while at high concentrations they can cause ... analyze how redox signaling unfolds in single cells and ... been developed jointly by the teams of LMU Professor ...
(Date:4/22/2014)... That person we all seem to know who we ... he or she isn,t unable to act but simply doesn,t ... A study of nearly 4,000 college students in ... may avoid making decisions and moving forward with life. Turns ... favorable, good, they just don,t like it as much as ...
(Date:4/22/2014)... Scientists of the ... the Medical University of Vienna, together with colleagues of the ... as viral genetic information, is prevented from entering the nucleus ... the protein ADAR1 moves from the cell nucleus into the ... of the virus. But how is the human genome protected ...
Breaking Medicine News(10 mins):Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:Neuroimaging: Live from inside the cell 2Health News:Neurotics don't just avoid action: They dislike it 2Health News:How the body fights against viruses 2Health News:How the body fights against viruses 3
... Orleans, La. -March 26, 2009 Nearly 90 percent of ... are caused by a blockage of blood vessels supplying ... published in Catheterization and Cardiovascular Interventions , the ... Interventions (SCAI), provides solid evidence of the effectiveness of ...
... Leading Neurological Testing Company Offers Top-Tier Developers And ... Market GamesBERKELEY, Calif., March 26 As the ... double-digit growth, the competition to create the next ... www.neurofocus.com ), the company that leads the global ...
... to Address Rare GI Cancers and Colorectal Screening ... American College of Gastroenterology and its more than ... Senator Kay Bailey Hutchinson today for the introduction ... Early detection, Research and Treatment) Act" and their ...
... imaging, researchers say , , THURSDAY, March 26 (HealthDay News) ... can better detect molecular changes inside the body that ... University chemists. , MRI uses hydrogen atoms in water ... radio waves, but the process requires a huge number ...
... 26 Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) and ... Roche has completed its acquisition of Genentech pursuant to ... member of the Roche Group. Roche had announced earlier ... offer, which expired on Wednesday, March 25. In connection ...
... Smith to carry message that good lifestyle choices help prevent ... Smith believes the best offense is a good defense - ... learned to be vigilant about diabetes in his own family. ... motivates me quite a bit. I think about all the ...
Cached Medicine News:Health News:Individualized stroke treatment available for patients, though underutilized 2Health News:NeuroFocus Launches NGame; New Suite of Neuromarketing Products and Services for the Videogame Industry Elite 2Health News:NeuroFocus Launches NGame; New Suite of Neuromarketing Products and Services for the Videogame Industry Elite 3Health News:Gastroenterologists Applaud Kennedy-Hutchinson Bill's Renewal of War on Cancer 2Health News:Gastroenterologists Applaud Kennedy-Hutchinson Bill's Renewal of War on Cancer 3Health News:Roche Completes Acquisition of Genentech 2Health News:Blue Cross and Blue Shield of Illinois Teams with Chicago Bears Coach Lovie Smith in Diabetes Awareness Drive 2Health News:Blue Cross and Blue Shield of Illinois Teams with Chicago Bears Coach Lovie Smith in Diabetes Awareness Drive 3Health News:Blue Cross and Blue Shield of Illinois Teams with Chicago Bears Coach Lovie Smith in Diabetes Awareness Drive 4
... Variant hemoglobin testing system ... testing for diabetes monitoring, ... testing, hemoglobinopathy screening and ... single test. It has ...
AcT 5diff OV enables low-volume labs to advance to 5-part differential analysis at an affordable price. This analyzer delivers accurate test results and a user-friendly software interface in a compac...
... LH 755 simplifies and automates ... expert automation and advanced technologies ... reliable, accurate results every time. ... slide quality with its slide-on-slide ...
For the quantitative determination of Creatine Kinase in serum....
Medicine Products: